← Back to Clinical Trials
Recruiting NCT07138872

NCT07138872 Hemodynamic Effects of Surgical Position in Prone vs. Supine Percutaneous Nephrolithotomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07138872
Status Recruiting
Phase
Sponsor Gaziosmanpasa Research and Education Hospital
Condition Percutaneous Nephrolithotomy (PCNL)
Study Type INTERVENTIONAL
Enrollment 84 participants
Start Date 2025-06-01
Primary Completion 2025-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Prone Position Percutaneous NephrolithotomySupine Position Percutaneous Nephrolithotomy (Galdakao-modified Valdivia)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 84 participants in total. It began in 2025-06-01 with a primary completion date of 2025-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This prospective, randomized controlled study evaluates the hemodynamic effects of prone and supine positions during percutaneous nephrolithotomy (PNL) for large kidney stones. Surgical position may influence intraoperative and postoperative hemodynamic stability. Prone positioning can increase intrathoracic pressure and reduce venous return, whereas supine positioning may provide greater hemodynamic stability. A total of 84 patients will be randomized to undergo PNL in prone or supine positions. Primary outcomes include changes in hemodynamic parameters during surgery. Results may guide surgical position selection, especially in patients with potential hemodynamic risk.

Eligibility Criteria

Inclusion Criteria: * ASA physical status I-III * Presence of renal calculi indicated for PNL Exclusion Criteria: * Pregnancy * Uncontrolled coagulopathy * Previous renal surgery * Severe cardiac, pulmonary, or neurological disease * Preoperative urinary tract infection (non-sterile urine culture) * Surgery duration \<60 minutes or \>120 minutes * Preoperative blood transfusion * Multiple access tracts

Contact & Investigator

Central Contact

ARİF BURAK KEÇEBAŞ, UROLOGY CLINIC DOCTOR

✉ arifkecebas@gmail.com

📞 +90 5412659978

Principal Investigator

Burak Arslan, CLINICAL PROFESSOR OF UROLOGY

STUDY DIRECTOR

Gaziosmanpaşa Training and Research Hospital, Urology Department, Istanbul, Türkiye

Frequently Asked Questions

Who can join the NCT07138872 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Percutaneous Nephrolithotomy (PCNL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07138872 currently recruiting?

Yes, NCT07138872 is actively recruiting participants. Contact the research team at arifkecebas@gmail.com for enrollment information.

Where is the NCT07138872 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07138872 clinical trial?

NCT07138872 is sponsored by Gaziosmanpasa Research and Education Hospital. The principal investigator is Burak Arslan, CLINICAL PROFESSOR OF UROLOGY at Gaziosmanpaşa Training and Research Hospital, Urology Department, Istanbul, Türkiye. The trial plans to enroll 84 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology